作者
Connie L Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith, Zhitao Ying, John F Gerecitano, Paul A Hamlin, Steve M Horwitz, Erel Joffe, Anita Kumar, Matthew J Matasar, Alison J Moskowitz, Craig H Moskowitz, Ariela Noy, Colette Owens, Lia M Palomba, David Straus, Gottfried von Keudell, Andrew D Zelenetz, Venkatraman E Seshan, Stefano Luminari, Luigi Marcheselli, Massimo Federico, Anas Younes
发表日期
2020/2/1
期刊
European Journal of Cancer
卷号
126
页码范围
78-90
出版商
Pergamon
简介
Background
Previous studies reported that early progression of disease (POD) after initial therapy predicted poor overall survival (OS) in patients with follicular lymphoma (FL). Here, we investigated whether pre-treatment imaging modality had an impact on prognostic significance of POD.
Methods
In this retrospective study, we identified 1088 patients with grade I–IIIA FL; of whom, 238 patients with stage II–IV disease were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), and 346 patients were treated with rituximab-based chemotherapy. Patients (N = 484) from the FOLL05 study served as an independent validation cohort. We risk-stratified patients based on pre-treatment radiographic imaging (positron-emission tomography [PET] versus computed tomography [CT]) and early POD status using event-defining and landmark analyses. A competing risk analysis …
学术搜索中的文章
CL Batlevi, F Sha, A Alperovich, A Ni, K Smith, Z Ying… - European Journal of Cancer, 2020